A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD),
placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with
Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).